Cerebral dopamine neurotrophic factor (CDNF) belongs to a newly discovered family of evolutionarily conserved neurotrophic factors. We demonstrate for the first time a therapeutic effect of CDNF in a unilateral 6-hydroxydopamine (6-OHDA) lesion model of Parkinson's disease in marmoset monkeys. Furthermore, we tested the impact of high chronic doses of human recombinant CDNF on unlesioned monkey...

Methamphetamine (METH) exerts significant neurotoxicity in experimental animals and humans when taken at high doses or abused chronically. Long-term abusers have decreased dopamine levels, and they are more likely to develop Parkinson's disease (PD). To date, few medications are available to treat the METH-induced damage of neurons. Glial cell line-derived neurotrophic factor (GDNF) has been pr...

Backgrounds: The loss of dopamine-secreting cells and the decrease in the status of antioxidant is associated with incidents of Parkinson's disease. The purpose of the present study was to determine the protective effect of a 12- weeks voluntary wheel running (VWR) along with the injection of eriobotrya japonica flower extract (EJFE, 200 mg/kg body weight, 3 days a week) on cer...

Parkinson's disease (PD) is a progressive and age-associated neurodegenerative disorder. Patients at different stages of the disease course have distinguished features, mainly in the number of dopaminergic neurons. Cerebral dopamine neurotrophic factor (CDNF) is a recently discovered neurotrophic factor, being deemed as a hopeful candidate for PD treatment. Here, we evaluated the efficacy of CD...

Cerebral dopamine neurotrophic factor (CDNF) protein has been shown to protect the nigrostriatal dopaminergic pathway when given as intrastriatal infusions in rat and mouse models of Parkinson's disease (PD). In this study, we assessed the neuroprotective effect of CDNF delivered with a recombinant adeno-associated viral (AAV) serotype 2 vector in a rat 6-hydroxydopamine (6-OHDA) model of PD. A...

Several neurotrophic factors (NTF) are shown to be neuroprotective and neurorestorative in pre-clinical animal models for Parkinson's disease (PD), particularly in models where striatal dopamine neuron innervation partially exists. The results of clinical trials on late-stage patients have been modest. Subthalamic deep brain stimulation (STN DBS) is a proven treatment for a selected group of ad...

Cerebral Dopamine Neurotrophic Factor (CDNF) and Mesencephalic Astrocyte-derived Neurotrophic factor (MANF) are members of a recently discovered family of neurotrophic factors (NTFs). Here, we used intranigral or intrastriatal lentiviral vector-mediated expression to evaluate their efficacy at protecting dopaminergic function in the 6-OHDA model of Parkinson's disease (PD). In contrast to the w...

We have solved the structures of mammalian mesencephalic astrocyte-derived neurotrophic factor (MANF) and conserved dopamine neurotrophic factor (CDNF). CDNF protects and repairs midbrain dopaminergic neurons in vivo; MANF supports their survival in culture and is also cytoprotective against endoplasmic reticulum (ER) stress. Neither protein structure resembles any known growth factor but the N...

Cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte-derived (MANF) are involved in neuroprotection mitigating endoplasmic reticulum (ER) stress the brain peripheral organs. In earlier work, an increase histone acetylation, following treatment with epigenetic modulator, valproic acid, was associated induction of CDNF MANF cultured cells rat brain. These findings prompted inv...

Background & Aims: The purpose of this research was to study the protective effect of pretreatment with a voluntary exercise on hippocampal level of cerebral dopamine neurotrophic factor (CDNF) after damage induced by intraventricular injection of 6–hydroxydopamine (6-OHDA) in rats. Methods: In this experimental study, 24 Wistar rats were randomly divided into 4 groups of healthy control, healt...